299 related articles for article (PubMed ID: 32041153)
21. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
22. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
24. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
25. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
[TBL] [Abstract][Full Text] [Related]
26. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
Crea F; Venalainen E; Ci X; Cheng H; Pikor L; Parolia A; Xue H; Nur Saidy NR; Lin D; Lam W; Collins C; Wang Y
Epigenomics; 2016 May; 8(5):721-31. PubMed ID: 27096814
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
[TBL] [Abstract][Full Text] [Related]
28.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
29. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
30. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
[TBL] [Abstract][Full Text] [Related]
31. The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
Dankert JT; Wiesehöfer M; Czyrnik ED; Singer BB; von Ostau N; Wennemuth G
PLoS One; 2018; 13(7):e0200472. PubMed ID: 30001402
[TBL] [Abstract][Full Text] [Related]
32. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
34. Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients.
Bhagirath D; Dahiya R; Majid S; Tabatabai ZL; Saini S
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31814621
[TBL] [Abstract][Full Text] [Related]
35. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141
[TBL] [Abstract][Full Text] [Related]
36. Neural Transcription Factors in Disease Progression.
Thaper D; Vahid S; Zoubeidi A
Adv Exp Med Biol; 2019; 1210():437-462. PubMed ID: 31900920
[TBL] [Abstract][Full Text] [Related]
37. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
38. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG; Sperger JM; Schehr JL; McKay RR; Emamekhoo H; Singh A; Schultz ZD; Bade RM; Stahlfeld CN; Gilsdorf CS; Hernandez CI; Wolfe SK; Mayberry RD; Krause HM; Bootsma M; Helzer KT; Rydzewski N; Bakhtiar H; Shi Y; Blitzer G; Kyriakopoulos CE; Kosoff D; Wei XX; Floberg J; Sethakorn N; Sharifi M; Harari PM; Huang W; Beltran H; Choueiri TK; Scher HI; Rathkopf DE; Halabi S; Armstrong AJ; Beebe DJ; Yu M; Sundling KE; Taplin ME; Lang JM
J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36317634
[TBL] [Abstract][Full Text] [Related]
39. Therapy considerations in neuroendocrine prostate cancer: what next?
Beltran H; Demichelis F
Endocr Relat Cancer; 2021 Jul; 28(8):T67-T78. PubMed ID: 34111024
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
